Medical Device News Magazine

DEACTIVATE by Xenex: Handheld LED Device Can Quickly Disinfect Surfaces in Confined Spaces

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

February 1

Deactivate is a high-powered, handheld LED device designed to quickly disinfect surfaces in confined spaces.

Xenex is known for its LightStrike™ Germ-Zapping Robots™, which have been deployed by hundreds of healthcare facilities worldwide for no-touch room disinfection. As a result of the COVID-19 pandemic, LightStrike robots are now used in airports, schools, hotels, sports arenas, police stations and correctional facilities, convention centers, and more to quickly disinfect large rooms and areas.

Recognizing the need for targeted disinfection in small spaces and compact areas, Xenex has launched Deactivate, which utilizes high-powered LEDs to create ultraviolet (UV) light proven to deactivate pathogens, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. Deactivate does not require warm-up or cool-down time, and does not leave behind any chemical residue. Post-disinfection, the area is immediately available for use.

“Our mission is to stop the pain and suffering caused by infections by destroying the pathogens that cause them. There are many businesses that need targeted, rapid disinfection, especially compact areas like dental exam rooms, ambulances, office cubicles, and cockpits. We wanted to offer an effective technology for disinfecting small spaces that are hard to clean and that’s what Deactivate provides,” said Irene Hahn, senior vice president of sales and marketing for Xenex.

Evidence-based. Testing performed at the Texas Biomedical Research Institute demonstrated that the Deactivate device achieves a 99% level of disinfection against SARS-CoV-2 in 30 seconds at 1 meter, 99% against vegetative bacteria (methicillin-resistant Staphylococcus aureus – also known as MRSA, Escherichia coli – also known as E.coli) in 1 minute at 1 meter, and 99% against bacterial spores in 2 minutes at 1 meter.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”